Results 181 to 190 of about 6,366 (244)

Improved survival with fludarabine‐based therapies in mixed phenotype acute leukaemia: A population‐based study using the WHO 2022 classification

open access: yesBritish Journal of Haematology, Volume 208, Issue 6, Page 2104-2112, June 2026.
Summary Mixed phenotype acute leukaemia (MPAL) is a rare subtype of acute leukaemia possessing significant therapeutic challenges, as no standardized, evidence‐based treatment regimen has been defined. In this nationwide study, we aimed to assess the effect of an acute lymphoid leukaemia (ALL)‐like regimen; an acute myeloid leukaemia (AML)‐like regimen;
Lisa‐Maj Christensen   +11 more
wiley   +1 more source

Second‐generation prokineticin PKR1 receptor agonists: Advancing cardioprotection against chemotherapy‐induced toxicity

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 12, Page 3377-3394, June 2026.
IS39, a novel non‐peptide PKR1 agonist, confers cardioprotection against doxorubicin‐induced toxicity. IS39 activates PKR1‐mediated pro‐survival signalling in cardiomyocytes, reducing reactive oxygen species (ROS), DNA damage and fibrosis markers. In vivo, IS39 preserves cardiac geometry and function in mice exposed to chronic doxorubicin challenge ...
Anais Audebrand   +8 more
wiley   +1 more source

PEGylated Chitosan Nanoparticles: Engineering Multifunctional Platforms for Targeted Cervical and Lung Cancer Treatment

open access: yesCancer Science, Volume 117, Issue 6, Page 1531-1542, June 2026.
Graphical representation of formation of self‐assembled PEGylated Chitosan Nanoparticles and their mechanism in tumor localization. ABSTRACT Polymer‐based nanocarriers have emerged as transformative platforms in cancer nanomedicine, enabling controlled and site‐specific delivery of therapeutic agents.
Prashant Kesharwani   +5 more
wiley   +1 more source

Daunorubicin‐45 Vs. Daunorubicin‐60 for Induction in Intermediate‐Age Patients of AML: Results From a Randomized Trial

open access: yesCancer Science, Volume 117, Issue 6, Page 1690-1700, June 2026.
Daunorubicin dose escalation from 45 to 60 mg/m2 provides no clinical benefit for AML patients aged 55–65. A dose of 45 mg/m2 should remain the preferred regimen for this population. ABSTRACT Daunorubicin dose optimization remains crucial for AML treatment.
Chunlin Zhou   +15 more
wiley   +1 more source

Plenary Abstracts Session & Oral Presentations

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Poster Sessions

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Choosing between Nivo‐AVD and BrECADD: Hodgkin lymphoma's new era

open access: yes
British Journal of Haematology, Volume 208, Issue 6, Page 2239-2242, June 2026.
Edward R. Scheffer Cliff   +2 more
wiley   +1 more source

Publication Only

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

ISEV2026 Abstract Book

open access: yes
Journal of Extracellular Vesicles, Volume 15, Issue S1, June 2026.
wiley   +1 more source

Pharmacogenetics of Anthracyclines

open access: yesPharmacogenomics, 2016
Anthracyclines constitute a fundamental part of the chemotherapy regimens utilized to treat a number of different malignancies both in pediatric and adult patients. These drugs are one of the most efficacious anticancer agents ever invented. On the other hand, anthracyclines are cardiotoxic.
C. Sági, Judit   +8 more
openaire   +4 more sources

Home - About - Disclaimer - Privacy